The 2026 annual meeting of the Society of Interventional Radiology (SIR) is quickly approaching. From April 11 through April 15 in Toronto, Canada, the SIR 2026 Annual Scientific Meeting will see top international radiologists gathering to present the latest groundbreaking research, technologies, and network amongst other IR professionals. Throughout the five-day conference, more than 400 presentations are scheduled to be presented across more than 130 sessions.

Today, we are previewing sessions on interventional oncology topics. Most sessions on interventional oncology topics take place on or after Sunday, April 12. The following preview represents just some of the SIR 2026 Annual Scientific Meeting sessions on interventional oncology topics. For a look at the complete schedule, including sessions on additional topics, visit the full schedule on the official meeting website.

Sunday, April 12

Emerging Indications for Percutaneous Ablation

  • 8:30 AM – 9:45 AM
  • Description: This workshop is divided into multiple topics: Percutaneous Pancreatic Ablation, Emerging Technologies and Expanding Ablation Indications (PEF/Histrotripsy Increasing Patient Eligibility), Pediatric Interventional Oncology; Ablation in Children, Percutaneous Ablative Therapy for Benign Thyroid Nodules, Percutaneous Ablative Therapy for Malignant Thyroid Nodules, and Breast Ablation. The workshop concludes with a Q&A segment.

Radioembolization – Next Level

  • 8:30 AM – 9:45 AM
  • Description: This course is divided into multiple subcourses: Debate: RadSeg (glass) vs. RadSeg (resin) - Best Practices and Data, Cases and Discussions, Debate: TARE in the Checkpoint Era (Case: Local Vascular Invasion), Debate Discussion, and Personalized Dosimetry - Why and How. The session concluded with a discussion segment.

Musculoskeletal Oncology

  • 1:15 PM – 2:30 PM
  • Description: This workshop is divided into multiple topics: Multidisciplinary Treatment of Osseous Metastases, Management of Painful Vertebral Metastases, Management of Desmoids, Extra-spinal Musculoskeletal Metastases: Role of Minimally Invasive Percutaneous Thermal Ablation, Percutaneous Osteosynthesis for Management of Osseous Metastases, Percutaneous Ablation in Oligometastatic Musculoskeletal Bone and Soft Tissue MEtastasis for Local Tumor Control, and Hot Topics and New Techniques in MSK Interventional Oncology. The session concludes with a Q&A segment.

Radioembolization 1

  • 3:00 PM – 4:30 PM
  • Description: This session is divided into multiple subsessions. Subsessions on interventional oncology include: Changing Utilization of Locoregional Therapies for HCC Across the United States, Target Trial Emulation: A Comparison of Resection, Ablation, and TARE for Early-Stage HCC - a Real-World Analysis, Transarterial Radioembolization (TARE) with Yttrium-90 (Y90) Glass Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis (PVT): Real-World Data from the PROACTIF Study, The Prognostic Value of Baseline Hemoglobin in Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization: An Institutional Experience from 705 Patients, Efficacy of Yttrium-90 Radiation Segmentectomy for Ablative Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis, and Robotics in Interventional Radiology.
Monday, April 13

Innovations in Ablation of Colorectal Liver Metastases

  • 8:30 AM – 9:45 AM
  • Description: This session is divided into multiple subsessions: Who is the Patient That Can Be Cured by Ablation?, Ablation Trials Affecting Survival: COLLISION and MAVERIC, Technique Mastery: COVER-ALL, ACCLAIM, NEW-COMMET, Evolving Role of Y-90 as Local Cure, and Role of Emerging Modalities: IRE, Histotripsy, PEF. The session will conclude with a Q&A segment.

General IO 1

  • 3:00 PM – 4:30 PM
  • Description: This session is divided into multiple subsessions: Novel Tract Cautery Device Increases Safety and Efficiency of Image-guided Percutaneous Needle Biopsies: A Retrospective Study of 120 Patients, Safety and Clinical Implications of Concurrent Biopsy of Neuroendocrine Liver Metastases at the Time of Liver-directed Therapy, Renal Biopsy Before vs During Ablation: A Retrospective Comparison of Biopsy Yield, Ablation Success, Complications, and the Frequency of Treating Benign Disease, Predictive Value of TI-RADS Scores for Thyroidectomy and Assessment of Inter-Rater Variability, Novel Acousto-Optic Sensor Stylet for Needle Tip Tracking, Needle Tip Imaging, and Tissue Characterization Compared to Capabilities of Electro Magnetic Tracking, Treatment Outcomes of Interventions for Fibroadipose Vascular Anomaly: A Systematic Review, Socioeconomic Factors Influencing Treatment Receipt of HCC: A Nationwide Analysis, Shift in Transarterial Modality of Choice for Hepatocellular Carcinoma and its Association with Achieving Complete Pathologic Necrosis, Development of Epirubicin-Loaded Lipiodol Beads by Two-Step Membrane Emulsification, and Endovascular Management of Tumor Thrombus: Comprehensive Analysis of Mechanical Thrombectomy and Interventional Strategies Across Cancer Types.

IO - Liver Ablation

  • 3:00 PM – 4:30 PM
  • Description: This session is divided into multiple subsessions. Some of the subsessions featured during this session include: Comparative Outcomes of Surgery and Contempoarary Interventional Radiology Therapies for Early-Stage Hepatocellular Carcinoma: A National Cancer Database Propensity-Weighted Analysis, Pulmonary Function Following Thermal Ablation of Lung Tumors: A Prospective Study, Insights from the FDA MAUDE Database on the Adverse Events Related to the Use of Histotripsy Device for Liver Cancer, Electromagnetic Navigation with Marker Guidance for Microwave Ablation of CT-Inconspicuous Liver Lesions: Prospective Feasibility and Outcomes Study, and more.

Radioembolization 2

  • 3:00 PM – 4:30 PM
  • Description: This session is divided into multiple subsessions. Some of the subsessions featured during this sessions include: COnsortium on Best Practice for RAdiation Segmentectomy (COBRAS) with Glass Microspheres: A U.S. Multicenter Study Evaluating PRedictors of Complete Pathologic Necrosis in Hepatocellular Carcinoma Prior to Liver Transplantation, Characterization of HCC Tumor Response Using Prospective Voxel Dosimetry in 90Y-radioembolization Clinical Trial RAPY90D, First-line Therapy Using Yttrium-90 Radioembolization Plus Systemic Gemcitabine, Cisplatin, and Capecitabine for Unresectable Intrahepatic Cholangiocarcinoma, and more.

Educational Exhibit Presentations - Interventional Oncology

  • 4:45 PM – 5:45 PM
  • Description: This sessions features multiple presentations including: The Hidden Risk of Histotripsy: Imaging Surveillance and Recognition of Complications, Contrast-enhanced Ultrasound Evaluation of  Histotripsy Liver Tumor Ablation: A Case Series of Expected and Unexpected Findings, Post-Renal Cryoablation Follow-up: A Standardized Approach, How to Perform Thyroid Nodule Radiofrequency Ablation: Trans-ISthmic Access, Moving-Shot Technique, and Safety Pearl, and Decoding Post-Ablative Imaging in the Lung: Endpoints, Follow-up Protocol, Recurrence and Complication Recognition After Image-Guided Ablation.
Tuesday, April 14

Advancing Interventional Oncology: Trials in Progress

  • 8:30 AM – 9:45 AM
  • Description: This session features multiple courses on interventional oncology topics, including: Redefining HCC: Ongoing Trials and Combination Strategies, Trials and Emerging Data in Lung Cancer Ablation and IO, Expanding the Role of IR in Renal Tumors: Ongoing Trials and Emerging Data, Emerging Frontiers: Trials in Pancreatic and Melanoma Interventions, Musculoskeletal Oncology: Emerging Trials in Bone and Soft Tissue Interventions, and more. The session will conclude with a Q&A segment.

General IO 2

  • 3:00 PM – 4:30 PM
  • Description: This session is divided into multiple subsessions, including: Percutaneous Endobiliary Radiofrequency Ablation Using Habib Probe for Unresectable Cholangiocarcinoma: Safety, Technical Feasibility, and Clinical Outcomes, Percutaneous Drainage of Malignant Biliary Obstruction Precluding Treatment: A Single Center Experience, CT-Guided Intervention: Reduction of Metal Artifact Using an Off-Axis Reconstruction Method, and Abdominal Wall Pseudohernia After Percutaneous Cryoablation for Renal Cell Carcinoma: A Six-Patients Case Series.

Radioembolization 3

  • 3:00 PM – 4:30 PM
  • Description: This session is divided into multiple subsessions, including: Comparison and Size- and Enhancement-Based Criteria for Evaluating Treatment Response and Survival Outcomes in Intrahepatic Cholangiocarcinoma Patients Treated with Yttrium-90 Radioembolization, Surgical and Pathologic Outcomes After Yttrium-90 Redioembolization Prior to Liver Resection or Transplant, Flow-Directed Catheter Therapeis in Yttrium-90 Radioembolization: A Systematic Review and Meta-Analysis, Outcomes of Resin Yttrium-90 Radioembolization with Advanced Dosimetry for Large HCC Tumors (>8cm): A Retrospective Cohort, and more.
Wednesday, April 15

Interventional Oncology 1

  • 9:45 AM – 11:00 AM
  • Description: This course is divided into multiple presentations, including: TACE vs TARE, Where Do We Standin in USA, Evolving Role of HCC Management in Japan, Korean Approach to HCC, Management of HCC in China: IR’s Role, HCC Management in A “Free Healthcare For All” System: Pros and Cons, and more.

Interventional Oncology 2

  • 9:45 AM – 11:00 AM
  • Description: This course is divided into multiple presentations including: European IO: Evolution of Locoregional HCC in Europe, Fibrolamellar HCC: How is IR an Integral Part of Care, Integrating TACE with PD-[L]1 Inhibitors, and MTT in HCC, Ablation vs Surgery: Dissecting COLLISION Study, Streamlinig and Same-Day Radioembolization with Resin Microspheres, and more.

General IO 3

  • 11:15 AM – 12:45 PM
  • Description: This session is divided into multiple subsessions, including: One-Stop Diagnosis and Treatment: CT Biopsy with Immediate Cryoablation in Medically Inoperable Patients with Suspicous Lung Nodules, Quality of Life Following Thermal Ablation of Lung Tumors: A Prospective Patient-Reported Outcomes Study, Predictors of Local Recurrence After Image-Guided Thermal Ablation for Stage IA Non-Small Cell Lung Caricnoma, and more.

IO Ablation Science

  • 11:15 AM – 12:45 PM
  • Description: This session is divided into multiple subsessions, including: Volumetric Minimum Ablation Margins Predict Local Control Outcomes for Patients Undergoing Renal Cryoblation, Using Voltage to Control Ablation Size in Integrated Nanosecond Pulse Irreversible Electroporation (INSPIRE) Treatments, Radiomic Signal Changes Following Histotripsy Ablation of Metastatic Hepatic Lesions, and more.

Radioembolization 4

  • 11:15 AM – 12:45 PM
  • Description: This session is divided into multiple subsessions, including: Analysis of Radiation Segmentecomy Treatment Planning in DOORwaY90: Selective Internal Radiation Therapy Using SIR-Spheres Y-90 Resin Microspeheres as First-line Treatement for Unresectable Hepatocellular Carcinoma Patients, Volume of Under-Dosed Tumor Predicts Survival After Radiation Secmentectomy of Hepatocellular Carcinoma Using Resin Microspheres, Safety and Efficacy of Superselective Y90 with Resin in 3 Cm or Smaller Liver Lesions, and more.

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.

Copyright © 2026 Guideline Central, all rights reserved.